We addressed these limitations in our study by evaluating the impact of SGLT2 on the progression of a VHL mutant ccRCC cell line in which the mutation had resulted in metabolic reprogramming of glucose metabolism. The gene discussed is VHL; the disease is nonpapillary renal cell carcinoma.